Breaking News

Piramal Pharma Solutions Completes 1,500th ADC Batch at Grangemouth Facility

Site has produced hundreds of distinct bioconjugates and supports clinical, commercial, and non‑GMP manufacturing activities.

Author Image

By: Charlie Sternberg

Associate Editor

The Grangemouth site team celebrates the completion of the 1,500th ADC batch.

Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., recently completed its 1,500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK. The site has produced hundreds of distinct bioconjugates and supports clinical, commercial, and non‑GMP manufacturing activities. Technical guidance for these programs is provided by subject matter experts from the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters